| Budget Amount *help |
¥199,810,000 (Direct Cost: ¥153,700,000、Indirect Cost: ¥46,110,000)
Fiscal Year 2023: ¥39,260,000 (Direct Cost: ¥30,200,000、Indirect Cost: ¥9,060,000)
Fiscal Year 2022: ¥40,300,000 (Direct Cost: ¥31,000,000、Indirect Cost: ¥9,300,000)
Fiscal Year 2021: ¥40,300,000 (Direct Cost: ¥31,000,000、Indirect Cost: ¥9,300,000)
Fiscal Year 2020: ¥40,300,000 (Direct Cost: ¥31,000,000、Indirect Cost: ¥9,300,000)
Fiscal Year 2019: ¥39,650,000 (Direct Cost: ¥30,500,000、Indirect Cost: ¥9,150,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we demonstrated that pathogenic osteoclasts, which are different from those maintaining normal bone metabolism, are formed in the arthritic joints, by means of our originally developed intravital imaging system accompanied with single cell analysis, and we succeeded in identifying an arthritic osteoclastogenic macrophage (AtoM) and another pathogenic macrophage AM1, which can induce AtoM in local inflammatory loci. We also showed that a transcription factor FoxM1 is important for the induction of AtoM, and we could also identify human AtoM by analyzing human samples. These results lead to the development of new therapies that can specifically inhibit pathological bone destruction caused by arthritis without affecting normal bone homeostasis.
|
